Wejo’s VP of Partnerships, Bret Scott speaks about the future of mobility and how connected car data impacts the world of autonomous, electric and shared.
Wejo’s VP of Partnerships, Bret Scott speaks about the future of mobility and how connected car data impacts the world of autonomous, electric and shared.
(Bloomberg) -- U.S. futures edged higher Tuesday as investors held out some hope of a deal on stimulus talks. Asian stocks slipped after a weak session on Wall Street overnight.S&P 500 Index futures climbed after a spokesman for House Speaker Nancy Pelosi said differences were narrowing in talks. Shares slipped in Japan and Australia. They fluctuated in China, Hong Kong and South Korea. European futures pointed lower. The 10-year Treasury yield steadied around 0.77% and the dollar held losses versus major peers. The yen dipped and the offshore yuan traded around its strongest since July 2018.Earlier, the S&P 500 Index fell to the lowest in almost two weeks as time draws short to reach agreement on a bill that could pass by Election Day on Nov. 3. The Australian dollar slid after comments from the central bank’s assistant governor that short-term rates could fall below zero. Oil extended losses after an OPEC+ meeting made no mention of any changes to a plan to further ease output cuts from January.Investors are weighing the chances of a resolution to stimulus talks before the Nov. 3 election. Federal Reserve policy makers have called for more fiscal support to shore up the recovery from the pandemic-induced recession.Pelosi and Treasury Secretary Steven Mnuchin “continued to narrow their differences” on a coronavirus relief package, a Pelosi aide said Monday. Democrats have resisted giving up on their priorities for local governments, workers, schools and health care.“Risky assets are losing their mojo after disheartening virus updates, countless stimulus banter that will not yield anything until after the election, and as central banks remain stuck in wait-and-see mode,” Edward Moya, a senior market analyst at Oanda in New York, said in a note. “The QE for life trade appears like it is not going away anytime soon, but that is not enough of reason to buy stocks now.”Meanwhile, global coronavirus cases exceeded 40 million, with the pandemic showing no signs of slowing. In the U.S., surges in Wisconsin and other battleground states pose a challenge for President Donald Trump two weeks before he stands for re-election.Here are some key events this week:Brexit trade talks are likely to continue at least into next week if the U.K. and EU fail to reach an agreement.The final presidential debate before the U.S. election, between President Donald Trump and former Vice President Joe Biden, will be live from Nashville, Tennessee on Thursday.These are some of the main moves in markets:StocksS&P 500 futures rose 0.3% as of 2:15 p.m. in Tokyo. The S&P 500 Index slipped 1.6%.Topix index fell 0.8%.Australia’s S&P/ASX 200 Index fell 0.7%.South Korea’s Kospi index was flat. Hong Kong’s Hang Seng Index fluctuated.Shanghai Composite Index was little changed. Euro Stoxx 50 futures fell 0.7%.CurrenciesThe yen was at 105.53 per dollar, down 0.1%.The Bloomberg Dollar Spot Index was little changed.The euro traded at $1.1780.The onshore yuan was at 6.6772 per dollar.The Aussie fell 0.5% to 70.41 U.S. cents.BondsThe yield on 10-year Treasuries held below 0.77%.Australia’s 10-year bond yield was at 0.75%.CommoditiesWest Texas Intermediate crude fell 0.6% to $40.57 a barrel.Gold slid 0.1% to $1,902.32 an ounce.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
The NRL is constantly updating the rules to weed out irrelevant ones, although there are cases of the abnormal laying dormant in the laws.
Socceroos coach Graham Arnold is reportedly considering quitting the national team as he weighs up an offer to join K-League outfit Seoul FC.
Trainer John Sargent has confirmed dual Randwick nominee Elizabeel will bypass the Brian Crowley Stakes in preference for a $1 million target.
Moderna Inc Chief Executive Officer Stéphane Bancel expects interim results from its COVID-19 vaccine trial in November and that the U.S government could give an emergency use nod in December, the Wall Street Journal reported https://www.wsj.com/articles/moderna-ceo-expects-covid-19-vaccine-interim-results-in-november-11603164001?mod=searchresults&page=1&pos=1 on Monday. Speaking at the newspaper's annual Tech Live conference, Bancel also said sufficient interim results from the study takes longer to get and that the government's permission to use the vaccine may not come until next year. The first interim analysis of the vaccine's efficacy will happen when 53 people in the entire study get symptomatic COVID-19, the report said.
Former senior US intelligence officials say the release of emails supposedly belonging to Hunter Biden has the "earmarks of a Russian information operation".
Moises Henriques continued his batting masterclass as NSW posted a heft first innings score in their Sheffield Shield match against Western Australia.
Retired four-star Adm.
The two gunmen who shot Mejid Hamzy, brother of notorious criminal Bassam Hamzy, are still on the run, but police say investigations have progressed.
On a windy August afternoon in 2017, Akitsinnguaq Ina Olsen was relaxing in the old harbour of Nuuk, Greenland's capital, when a Chinese icebreaker sailed unannounced into the Arctic island's territorial waters. The Chinese ship was one of a growing number of unexpected arrivals in Arctic waters as shrinking sea ice has fast-tracked a race among global powers for control over resources and waterways. Both China and Russia have been making increasingly assertive moves in the region, and after the U.S. Secretary of State Mike Pompeo last year said now is "America's moment to stand up as an Arctic nation and for the Arctic's future," military activity is stepping up.
As we flit up and down levels in this dystopian elevator dance, I find myselfgripped with hiraeth, a Welsh word to describe a nostalgia for a home you cannever return to.
If you live on a street that contains one of this year's most desirable babynames, you could see the value of your property rocket.
"The virus has genetically moved a bit, but it has not changed in terms of itspropensity and its ability to cause disease and to cause death.
EBITDA fixed herd prices (FHP) for Q3 2020 decreased to 7,253 mEUR (Q3 2019: 9,052 kEUR), corresponding to an EBITDA margin FHP of 29.3% (Q3 2019: 31.0%). Q3 harvest influenced EBITDA margin significantly, as it is EBITDA without revenue. Harvest EBITDA was Q3 2020 3.8 mEUR and Q3 2019 3.8 mEUR, EBITDA margin FHP (without harvest) was 14.1% (Q3 2019: 18.0%).Sales prices in Q3 were 1.12 EUR/kg live weight down from 1,14 EUR/kg (Q2 2020). The price decrease from Q2 has been driven by a Corona impact on the supply chain and effect from ASF outbreak in Germany, partly compensated with that Russian prices have rebounded somewhat due to season and increasing export from Russia to Vietnam. The outlook is highly uncertain with the ASF situation in China/Germany and a potential rebound of Coronavirus impacting supply chains. Feed prices in Q3 were 229 EUR/T as in Q2 2020 (compared to 244 EUR/T Q3 2019). A significant amount of grain is hedged until harvest 2021 either in storage or contract, reducing feed price fluctuations. The herd valuation in Q3 decreased by 3,821 mEUR (compared to 30.06.2020). Lower prices drove the decrease in EU and Lithuania, partly compensated by Russia. Free cash flow was 3,771 kEUR in Q3 2020 (Q3 2019: 2.294 kEUR). Net interest-bearing debt has last quarter decreased from 68,3 mEUR to 64,0 mEUR driven by operational cashflow Q3 (3,1 mEUR) and devaluating in Q3 (2,4 mEUR).Idavang expects IFC put option being called during November month. Further informationBondholders - Claus Baltsersen, CEO phone +370 (685) 34 104Media - Jytte Rosenmaj, Board Member phone +45 26 73 46 99Attachment * Company announcement no 22 2020 Q3 2020 Idavang Interim Report
Operational The fleet utilisation rate in the third quarter of 2020 was 16.4 per cent (Q3 2019: 48.2 per cent). Prosafe has been in discussions with several clients about existing contracts in light of Covid-19 and the oil price collapse, and has managed to protect its order book by moving contracts from 2020 to 2021 with some further extensions. Please see the update per vessel below. Prosafe continues to claim full contract value from EnQuest relating to the planned Thistle project for the Safe Zephyrus. Prosafe has agreed with Shell to defer and amend the contract for the Safe Zephyrus at the Shearwater platform. The revised firm duration of the contract is 115 days and the contract is scheduled to commence in March 2021. Shell has the option of adding 30 or 45 days to the front end, resulting in a possible earlier commencement date. In addition, Shell retains the option to extend the contract after the firm duration by up to 30 days. The Safe Zephyrus is currently laid up at Averøy yard in Norway preparing to conduct her five-yearly special periodic survey. Safe Caledonia is currently laid up in the UK. The vessel is scheduled to commence a 162-day contract with a 30-day option for Total at Elgin in the UK from Q1 2021. This contract was originally scheduled to commence in 2020. Safe Eurus has been providing safety and maintenance support to Petrobras during a three-year contract since November 2019. From April 2020, the Safe Eurus was suspended for 120 days at zero rate. The vessel has been on standby rate since early August and recommenced operations on 24 September 2020. The original three-year and 222-day firm contract for the Safe Notos that was due to complete in July 2020 was suspended for 120 days at zero rate from April 2020. The vessel was back on standby rate in early August 2020 and resumed operations in early October 2020. Safe Concordia was idle in the quarter and is laid up in Brazil. Safe Scandinavia, Safe Boreas and Regalia were idle in the quarter and are laid up in Norway. Regalia has been marketed for recycling with possible commencement of recycling in Q1 2021. Although the impact from Covid-19 on the macro environment has been challenging, the company has successfully implemented proper safety measurements at workplaces and vessels to protect people and assets, as well as several cost-saving initiatives to protect liquidity. Financial Please refer to separate press release from 1 October 2020 regarding the ongoing discussion with lenders about a long-term financial solution for the company. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to https://www.prosafe.com Stavanger, 20 October 2020 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24 30 / +47 907 65 155 Stig Harry Christiansen, Deputy CEO and CFO Phone: +47 51 64 25 17 / +47 478 07 813 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
EUR 110 million investment will increase capsule production by +60% Press release Amsterdam, 20 October 2020 JDE Peet’s (EURONEXT: JDEP), the world's largest pure-play coffee and tea group by revenue, today announced plans to invest EUR 110 million in its global supply network through the installation of new high-speed aluminium coffee capsule production lines. These additional lines will be installed in stages over the coming 18 months beginning with new lines in Andrézieux, France that will become operational in the course of H1 2021. These investments are the latest in a series of manufacturing capacity expansions designed to meet the increased consumer demand for single serve products. The total EUR 110 million investment will increase JDE Peet’s capsule production capacity by +60% to meet the rapidly expanding consumer demand for premium Single Serve coffee experiences.“The total Single Serve coffee category has seen tremendous growth, a trend that is expected to continue, with aluminium coffee capsules serving as a strong driver,” said Fabien Simon, CEO of JDE Peet’s. “We were the first to bring aluminium coffee capsules into grocery stores back in 2016, driving general category growth, increasing consumer choice and creating value for our customers. This new strategic investment ensures that JDE Peet’s is well positioned within the market as this category continues to expand.” Since pioneering the aluminium coffee capsule market in grocery retail back in 2016, JDE Peet’s has quickly gained significant market share in one of the fastest growing premium coffee segments and has successfully applied this technology throughout its brand portfolio in 47 markets. According to Euromonitor, JDE Peet’s represents ~13% of the total Single Serve coffee category, which is currently valued at EUR 17 billion and is expected to grow at an annual rate of 7.8% to EUR 23 billion by 2024, fuelled by consumers’ increasing preference for premium Single Serve coffee products. Since the introduction of aluminium coffee capsules in 2016, the Andrézieux factory has become a major employer in the Auvergne-Rhône-Alpes region, growing its workforce by more than 60% (150 jobs). The factory produces more than 400 different types of coffee and recently celebrated the production of its 10 billionth aluminium coffee capsule.Enquiries Media Michael Orr (EN) | Nathalie Rolland (FR) Media@JDEPeets.comInvestors & Analysts Robin Jansen +31 6 1594 4569 Robin.Jansen@JDEcoffee.com About JDE Peet’s JDE Peet’s is the world's largest pure-play coffee and tea group by revenue, serving approximately 130 billion cups of coffee and tea in the financial year ended 31 December 2019 in more than 100 developed and emerging countries. With a portfolio of more than 50 leading global, regional and local coffee and tea brands, JDE Peet’s offers an extensive range of high-quality and innovative coffee and tea products and solutions to serve consumer needs across markets, consumer preferences and price levels. In 2019, JDE Peet’s generated total sales of EUR 6.9 billion and had on average 21,255 employees worldwide. The JDE Peet’s global portfolio includes: Jacobs, Peet’s, L’OR, Senseo, Tassimo and Ti Ora. For more information please visit JDE Peet’s website.Attachment * 201020 JDE Peets to significantly expand its aluminium coffee capsule production capacity
Geneva, Switzerland and Boston, MA – October 20, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of a poster at the ASRM 2020 Virtual Scientific Congress and Expo.Poster number P-482: The Effect of the Oral Oxytocin Antagonist, Nolasiban, On Pregnancy Rates in Women Undergoing Embryo Transfer Following IVFDr. Georg Griesinger, Professor at Luebeck University, Germany, and chair of the Department of Gynecological Endocrinology and Reproductive Medicine, University Hospital of Schleswig-Holstein, is lead author of a poster presenting results from a meta-analysis of the clinical trials and a mechanism of action study of nolasiban, an oxytocin receptor antagonist being developed for its potential to increase pregnancy rates following in vitro fertilization (IVF). Results support the further evaluation of higher doses and/or alternate regimens of nolasiban. ObsEva is partnering with YuYuan BioScience Technology, a Chinese company, for the development of nolasiban.The related abstract is scheduled to be published online in the Fertility and Sterility Abstract Supplement in October 2020.About ObsEvaObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving embryo transfer (ET) outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.About Nolasiban Nolasiban (previously known as OBE001), is an oral oxytocin receptor antagonist which was licensed from Merck KGaA, Darmstadt, Germany, in 2013. ObsEva retains worldwide, exclusive, commercial rights (ex China).About Assisted Reproductive Technology Infertility affects about 10% of reproductive-aged couples, with more than two million assisted reproductive technology (ART) treatments (including IVF and intracytoplasmic sperm injection (ICSI)) performed worldwide each year. In China, more than 950,000 ART cycles (IVF, ICSI, fetal ET) were performed in 2017 (National Health Commission of the PRC, presented at the 23rd International Federation of Fertility Societies conference in Shanghai, 2019).While the success of ART depends on multiple factors including ovarian response, fertilization, embryo quality and ET procedure, a successful pregnancy ultimately hinges on the receptivity of the uterus to accept embryo implantation. Uterine contractions at the time of ET, as well as suboptimal thickness of the uterine wall and insufficient blood flow to the uterus, may impair the implantation of the embryo.About YuYuan Bioscience TechnologyYuYuan Bioscience Technology is a leading biopharmaceutical company based in China focused on discovering, developing and commercializing innovative medicines for unmet medical needs in the assisted reproductive area. The company continues to introduce a competitive portfolio of therapeutic programs aimed at helping to bring more solutions to this field. YuYuan Bioscience has a top class leadership team with deep experience at assisted reproductive therapeutics and within biotech organizations. The team has a strong track record of success – successfully having taken drug candidates into clinical trials in China, secured regulatory approvals and achieved great market success. YuYuan Bioscience has always adhered to the development concept of “doing moral business, craving long-lasting career”, providing comprehensive, accurate and professional services for China's assisted reproductive medical field.Cautionary Note Regarding Forward Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include statements regarding the potential of nolasiban to improve pregnancy rates following IVF. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development and related regulatory reviews and approvals, including the risk that the results of earlier clinical trials may not be predictive of the results of later-stage clinical trials, related interactions with regulators, the impact of the novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2019, the Risk Factors disclosed in ObsEva’s Report on Form 6-K filed with the Securities and Exchange Commission (SEC) on August 6, 2020 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.obseva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.For further information, please contact: CEO Office contact Shauna Dillon Shauna.firstname.lastname@example.org +41 22 552 1550 Attachment * Press Release in Pdf
Recruitment on track to be completed before year-end Gosselies, Belgium, 20 October 2020, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it has already completed over 50% of its treated patients in its Phase III clinical study with the improved viscosupplement, JTA-004, in patients with knee osteoarthritis. At the current recruitment rate, and assuming no further significant disruption of health care systems worldwide due to the continuing COVID-19 pandemic, Bone Therapeutics expects to complete patient enrollment before year-end. Topline results are anticipated on the 3-month primary endpoint and 6-month follow-up period in the second half of 2021.“The COVID-19 pandemic has posed major challenges to patient recruitment across the industry. In spite of this, Bone Therapeutics, with the support of NBCD, has been able to treat over 50% of the patients in the JTA-004 Phase III trial in just over four months, since it started recruiting in mid-May,” said Miguel Forte, CEO, Bone Therapeutics. “This significant progress keeps us on schedule to complete recruitment before the end of the year and release topline data by second half next year. A positive outcome for this pivotal study would be a major achievement for the high unmet medical need of the estimated 250 million patients worldwide suffering from knee osteoarthritis, a very painful and debilitating condition.”The JTA-004 Phase III study is a controlled, randomized, double-blind trial. It is evaluating the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee compared to placebo or Hylan G-F 20, the leading current osteoarthritis treatment on the market. The study is being conducted in six European countries as well as Hong Kong SAR. Since the initiation of the recruitment in mid-May 2020, 50% of the targeted assessable patients have already been treated. The study plans to enroll 676 patients fulfilling the protocol criteria with mild to moderate symptomatic knee osteoarthritis.JTA-004 is Bone Therapeutics’ next generation of intra-articular injectables for the treatment of osteoarthritic pain in the knee. Consisting of a unique mix of hyaluronic acid - a natural component of knee synovial fluid, plasma proteins, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain. In a previous randomized, double-blind Phase II study involving 164 patients, JTA-004 showed superior clinical benefit with an improved pain relief at 3 and 6 months compared to Hylan G-F 20, the global market leader in osteoarthritis treatment. About Bone TherapeuticsBone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a, diversified portfolio of cell and biologic therapies at different stages ranging from pre-clinical programs in immunomodulation to mid-to-late stage clinical development for orthopedic conditions, targeting markets with large unmet medical needs and limited innovation.Osteoarthritis (OA), also known as degenerative joint disease, is the most common chronic joint condition in which the protective cartilage in the joints progressively break down resulting in joint pain, swelling, stiffness and limited range of motion. The knee is one of the joints that are mostly affected by osteoarthritis, with an estimated 250 million cases worldwide.Bone Therapeutics is developing an off-the-shelf next-generation improved viscosupplement, JTA-004, which is currently in Phase III development for the treatment of pain in knee osteoarthritis. Consisting of a unique combination of plasma proteins, hyaluronic acid - a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain and inflammation. Positive Phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement.Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at www.bonetherapeutics.com. For further information, please contact:Bone Therapeutics SA Miguel Forte, MD, PhD, Chief Executive Officer Jean-Luc Vandebroek, Chief Financial Officer Tel: +32 (0)71 12 10 00 email@example.comFor Belgian Media and Investor Enquiries: Bepublic Catherine Haquenne Tel: +32 (0)497 75 63 56 firstname.lastname@example.orgInternational Media Enquiries: Image Box Communications Neil Hunter / Michelle Boxall Tel: +44 (0)20 8943 4685 email@example.com / firstname.lastname@example.orgFor French Media and Investor Enquiries: NewCap Investor Relations & Financial Communications Pierre Laurent, Louis-Victor Delouvrier and Arthur Rouillé Tel: +33 (0)1 44 71 94 94 email@example.comFor US Media and Investor Enquiries: LHA Investor Relations Yvonne Briggs Tel: +1 310 691 7100 firstname.lastname@example.orgCertain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Priceless Planet Coalition Expands, Unites Businesses and Consumers Worldwide to Preserve the Environment
Amazon announces a season of giving, donating millions of items through product and monetary donations to over a thousand charities around the world.